Literature DB >> 18404671

Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India.

Marc Arbyn1, Rengaswamy Sankaranarayanan, Richard Muwonge, Namory Keita, Amadou Dolo, Charles Gombe Mbalawa, Hassan Nouhou, Boblewende Sakande, Ramani Wesley, Thara Somanathan, Anjali Sharma, Surendra Shastri, Parthasarathy Basu.   

Abstract

Cervical cancer is the main cancer among women in sub-Saharan Africa, India and other parts of the developing world. Evaluation of screening performance of effective, feasible and affordable early detection and management methods is a public health priority. Five screening methods, naked eye visual inspection of the cervix uteri after application of diluted acetic acid (VIA), or Lugol's iodine (VILI) or with a magnifying device (VIAM), the Pap smear and human papillomavirus testing with the high-risk probe of the Hybrid Capture-2 assay (HC2), were evaluated in 11 studies in India and Africa. More than 58,000 women, aged 25-64 years, were tested with 2-5 screening tests and outcome verification was done on all women independent of the screen test results. The outcome was presence or absence of cervical intraepithelial neoplasia (CIN) of different degrees or invasive cervical cancer. Verification was based on colposcopy and histological interpretation of colposcopy-directed biopsies. Negative colposcopy was accepted as a truly negative outcome. VIA showed a sensitivity of 79% (95% CI 73-85%) and 83% (95% CI 77-89%), and a specificity of 85% (95% CI 81-89%) and 84% (95% CI 80-88%) for the outcomes CIN2+ or CIN3+, respectively. VILI was on average 10% more sensitive and equally specific. VIAM showed similar results as VIA. The Pap smear showed lowest sensitivity, even at the lowest cutoff of atypical squamous cells of undetermined significance (57%; 95% CI 38-76%) for CIN2+ but the specificity was rather high (93%; 95% CI 89-97%). The HC2-assay showed a sensitivity for CIN2+ of 62% (95% CI 56-68%) and a specificity of 94% (95% CI 92-95%). Substantial interstudy variation was observed in the accuracy of the visual screening methods. Accuracy of visual methods and cytology increased over time, whereas performance of HC2 was constant. Results of visual tests and colposcopy were highly correlated. This study was the largest ever done that evaluates the cross-sectional accuracy of screening tests for cervical cancer precursors in developing countries. The merit of the study was that all screened subjects were submitted to confirmatory investigations avoiding to verification bias. A major finding was the consistently higher sensitivity but equal specificity of VILI compared with VIA. Nevertheless, some caution is warranted in the interpretation of observed accuracy measures, since a certain degree of gold standard misclassification cannot be excluded. Because of the correlation between visual screening tests and colposcopy and a certain degree of over-diagnosis of apparent CIN2+ by study pathologists, it is possible that both sensitivity and specificity of VIA and VILI were overestimated. Gold standard verification error could also explain the surprisingly low sensitivity of HC2, which contrasts with findings from other studies. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404671     DOI: 10.1002/ijc.23489

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  87 in total

1.  Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India.

Authors:  Haripriya Vedantham; Michelle I Silver; B Kalpana; C Rekha; B P Karuna; K Vidyadhari; S Mrudula; Brigitte M Ronnett; K Vijayaraghavan; Gayatri Ramakrishna; Pavani Sowjanya; Shantha Laxmi; Keerti V Shah; Patti E Gravitt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

2.  Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.

Authors:  Fang-Hui Zhao; Margaret Jane Lin; Feng Chen; Shang-Ying Hu; Rong Zhang; Jerome L Belinson; John W Sellors; Silvia Franceschi; You-Lin Qiao; Philip E Castle
Journal:  Lancet Oncol       Date:  2010-11-11       Impact factor: 41.316

3.  International Image Concordance Study to Compare a Point-of-Care Tampon Colposcope With a Standard-of-Care Colposcope.

Authors:  Jenna L Mueller; Elizabeth Asma; Christopher T Lam; Marlee S Krieger; Jennifer E Gallagher; Alaattin Erkanli; Roopa Hariprasad; J S Malliga; Lisa C Muasher; Bariki Mchome; Olola Oneko; Peyton Taylor; Gino Venegas; Anthony Wanyoro; Ravi Mehrotra; John W Schmitt; Nimmi Ramanujam
Journal:  J Low Genit Tract Dis       Date:  2017-04       Impact factor: 1.925

4.  Physical after effects and clients satisfaction following colposcopy and cervical biopsy in a Nigerian population.

Authors:  C A Okonkwo; M C Ezeanochie; B N Olagbuji
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

5.  Optical Imaging: Future Tool in Detection of Pre-cancerous and Cancerous Lesions of Cervix and Its Comparison to Colposcopy.

Authors:  Kiran Pandey; Ajay Bhagoliwal; Sonal Jain
Journal:  J Obstet Gynaecol India       Date:  2014-07-15

6.  Correlation of colposcopy using Reid colposcopic index with histopathology- a prospective study.

Authors:  Geeta Sanjeevkumar Durdi; Bhavana Yatin Sherigar; Anita Mohan Dalal; Babasaheb Raosaheb Desai; Prakash Rudrappa Malur
Journal:  J Turk Ger Gynecol Assoc       Date:  2009-12-01

7.  A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo.

Authors:  S Hovland; M Arbyn; A K Lie; W Ryd; B Borge; E J Berle; H Skomedal; T M Kadima; L Kyembwa; E M Billay; D Mukwege; R B Chirimwami; T M Mvula; P J Snijders; C J L M Meijer; F Karlsen
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

Review 8.  Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review.

Authors:  Eric Chamot; Sibylle Kristensen; Jeffrey S A Stringer; Mulindi H Mwanahamuntu
Journal:  BMC Womens Health       Date:  2010-04-01       Impact factor: 2.809

9.  Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India.

Authors:  Patti E Gravitt; Proma Paul; Hormuzd A Katki; Haripriya Vendantham; Gayatri Ramakrishna; Mrudula Sudula; Basany Kalpana; Brigitte M Ronnett; K Vijayaraghavan; Keerti V Shah
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

Review 10.  How to evaluate emerging technologies in cervical cancer screening?

Authors:  Marc Arbyn; Guglielmo Ronco; Jack Cuzick; Nicolas Wentzensen; Philip E Castle
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.